MX2013014489A - Peptidos sema5b y vacunas que incluyen los mismos. - Google Patents

Peptidos sema5b y vacunas que incluyen los mismos.

Info

Publication number
MX2013014489A
MX2013014489A MX2013014489A MX2013014489A MX2013014489A MX 2013014489 A MX2013014489 A MX 2013014489A MX 2013014489 A MX2013014489 A MX 2013014489A MX 2013014489 A MX2013014489 A MX 2013014489A MX 2013014489 A MX2013014489 A MX 2013014489A
Authority
MX
Mexico
Prior art keywords
peptides
polynucleotides
aforementioned
sema5b
modified versions
Prior art date
Application number
MX2013014489A
Other languages
English (en)
Spanish (es)
Inventor
Takuya Tsunoda
Ryuji Osawa
Sachico Yoshimura
Tomohisa Watanabe
Gaku Nakayama
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2013014489A publication Critical patent/MX2013014489A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
MX2013014489A 2011-06-10 2012-06-07 Peptidos sema5b y vacunas que incluyen los mismos. MX2013014489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495819P 2011-06-10 2011-06-10
PCT/JP2012/003740 WO2012169200A1 (en) 2011-06-10 2012-06-07 Sema5b peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
MX2013014489A true MX2013014489A (es) 2014-03-27

Family

ID=47295783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014489A MX2013014489A (es) 2011-06-10 2012-06-07 Peptidos sema5b y vacunas que incluyen los mismos.

Country Status (14)

Country Link
US (1) US9187556B2 (enExample)
EP (1) EP2718435A4 (enExample)
JP (1) JP2014519311A (enExample)
KR (1) KR20140026543A (enExample)
CN (1) CN103620033A (enExample)
AU (1) AU2012265677A1 (enExample)
BR (1) BR112013031056A2 (enExample)
CA (1) CA2838633A1 (enExample)
IL (1) IL228995A0 (enExample)
MX (1) MX2013014489A (enExample)
RU (1) RU2013158399A (enExample)
SG (1) SG195047A1 (enExample)
TW (1) TW201302800A (enExample)
WO (1) WO2012169200A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
WO2025072522A1 (en) * 2023-09-29 2025-04-03 The Regents Of The University Of California Neojunction-derived cancer antigen epitopes, specific t cell receptors (tcrs) for immunotherapy, and discovery platform for the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
EP2837636B1 (en) * 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof

Also Published As

Publication number Publication date
TW201302800A (zh) 2013-01-16
US20140178409A1 (en) 2014-06-26
US9187556B2 (en) 2015-11-17
SG195047A1 (en) 2013-12-30
EP2718435A1 (en) 2014-04-16
CA2838633A1 (en) 2012-12-13
BR112013031056A2 (pt) 2016-11-29
KR20140026543A (ko) 2014-03-05
WO2012169200A1 (en) 2012-12-13
EP2718435A4 (en) 2014-11-26
RU2013158399A (ru) 2015-07-20
AU2012265677A1 (en) 2014-01-16
CN103620033A (zh) 2014-03-05
JP2014519311A (ja) 2014-08-14
IL228995A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CY1123762T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρiκου καρκινου
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
MX2015012012A (es) Peptidos de kntc2 y vacunas que los contienen.
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
CY1124738T1 (el) Συνθεσεiς εμβολιων που περιλαμβανουν τρυπτοφανη 2,3-διοξυγεναση ή θραυσματα αυτης
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
MX2014001675A (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
CY1122083T1 (el) Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ)
MX2013006014A (es) Peptidos tomm34 y vacunas que los incluyen.
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
MX2015007015A (es) Peptidos sema5b y vacunas que contienen los mismos.
CY1116819T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas
PH12012501935A1 (en) Ect2 peptides and vaccines including the same
AR100926A1 (es) Inmunoterapia contra varios tumores de la sangre, en particular contra la leucemia linfoide crónica (llc)